Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 126

1.

A Novel Liquid Fiducial Marker in Esophageal Cancer Image Guided Radiation Therapy: Technical Feasibility and Visibility on Imaging.

Machiels M, Voncken FEM, Jin P, van Dieren JM, Bartels-Rutten A, Alderliesten T, Aleman BMP, van Hooft JE, Hulshof MCCM.

Pract Radiat Oncol. 2019 Jul 4. pii: S1879-8500(19)30189-4. doi: 10.1016/j.prro.2019.06.018. [Epub ahead of print]

PMID:
31279938
2.

Fatigue level changes with time in long-term Hodgkin and non-Hodgkin lymphoma survivors: a joint EORTC-LYSA cross-sectional study.

Busson R, van der Kaaij M, Mounier N, Aleman BMP, Thiéblemont C, Stamatoullas A, Ribrag V, Tilly H, Haioun C, Casasnovas RO, Kluin-Nelemans HC, Henry-Amar M.

Health Qual Life Outcomes. 2019 Jul 2;17(1):115. doi: 10.1186/s12955-019-1186-x.

3.

Setting up a national infrastructure for survivorship care after treatment for Hodgkin lymphoma.

Nijdam A, Dekker N, Aleman BMP, van 't Veer MB, Daniels LA, van der Maazen RW, Janus CPM, de Weijer RJ, Zijlstra JM, Stedema FG, Ta BD, Posthuma EFM, Manenschijn A, Dielwart MFH, Bilgin YM, van den Heuvel MJ, Boersma RS, van Leeuwen FE, Raemaekers JMM; BETER consortium.

Br J Haematol. 2019 Aug;186(4):e103-e108. doi: 10.1111/bjh.15936. Epub 2019 May 15. No abstract available.

PMID:
31090916
4.

Small Cell Carcinoma of the Esophagus: A Nationwide Analysis of Treatment and Outcome at Patient Level in Locoregional Disease.

Jeene PM, Geijsen ED, Muijs CT, Rozema T, Aleman BMP, Muller K, Baas JM, Nuyttens JJ, Wouterse S, Braam PM, Oppedijk V, Ceha HM, Cnossen J, Spruit P, Bongers EM, Berbée M, Mook S, Hulshof MCCM.

Am J Clin Oncol. 2019 Jun;42(6):534-538. doi: 10.1097/COC.0000000000000546.

5.

Salvage Treatment and Survival for Relapsed Follicular Lymphoma Following Primary Radiation Therapy: A Collaborative Study on Behalf of ILROG.

Binkley MS, Brady JL, Hajj C, Chelius M, Chau K, Balogh A, Levis M, Filippi AR, Jones M, Ahmed S, MacManus M, Wirth A, Oguchi M, Vistisen AK, Andraos TY, Ng AK, Aleman BMP, Choi SH, Kirova YM, Hardy S, Reinartz G, Eich HT, Bratman SV, Constine LS, Suh CO, Dabaja B, El-Galaly TC, Hodgson DC, Ricardi U, Yahalom J, Mikhaeel NG, Hoppe RT.

Int J Radiat Oncol Biol Phys. 2019 Jul 1;104(3):522-529. doi: 10.1016/j.ijrobp.2019.03.004. Epub 2019 Mar 8.

PMID:
30858143
6.

Diagnostic performance of MRI for assessment of response to neoadjuvant chemoradiotherapy in oesophageal cancer.

Vollenbrock SE, Voncken FEM, van Dieren JM, Lambregts DMJ, Maas M, Meijer GJ, Goense L, Mook S, Hartemink KJ, Snaebjornsson P, Ter Beek LC, Verheij M, Aleman BMP, Beets-Tan RGH, Bartels-Rutten A.

Br J Surg. 2019 Apr;106(5):596-605. doi: 10.1002/bjs.11094. Epub 2019 Feb 25.

7.

Elevated Pretreatment CEA and CA19-9 Levels are Related to Early Treatment Failure in Esophageal Adenocarcinoma.

van der Kaaij RT, Voncken FEM, van Dieren JM, Snaebjornsson P, Korse CM, Grootscholten C, Aleman BMP, van Sandick JW.

Am J Clin Oncol. 2019 Apr;42(4):345-350. doi: 10.1097/COC.0000000000000525.

PMID:
30724779
8.

Overall and disease-specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer.

Rigter LS, Schaapveld M, Janus CPM, Krol ADG, van der Maazen RWM, Roesink J, Zijlstra JM, van Imhoff GW, Poortmans PMP, Beijert M, Lugtenburg PJ, Visser O, Snaebjornsson P, van Eggermond AM, Aleman BMP, van Leeuwen FE, van Leerdam ME.

Cancer Med. 2019 Jan;8(1):190-199. doi: 10.1002/cam4.1922. Epub 2018 Dec 27.

9.

Genetic susceptibility to radiation-induced breast cancer after Hodgkin lymphoma.

Opstal-van Winden AWJ, de Haan HG, Hauptmann M, Schmidt MK, Broeks A, Russell NS, Janus CPM, Krol ADG, van der Baan FH, De Bruin ML, van Eggermond AM, Dennis J, Anton-Culver H, Haiman CA, Sawyer EJ, Cox A, Devilee P, Hooning MJ, Peto J, Couch FJ, Pharoah P, Orr N, Easton DF, Aleman BMP, Strong LC, Bhatia S, Cooke R, Robison LL, Swerdlow AJ, van Leeuwen FE.

Blood. 2019 Mar 7;133(10):1130-1139. doi: 10.1182/blood-2018-07-862607. Epub 2018 Dec 20.

PMID:
30573632
10.

Cardiovascular Disease Risk After Treatment-Induced Premature Ovarian Insufficiency in Female Survivors of Hodgkin Lymphoma.

Krul IM, Opstal-van Winden AWJ, Janus CPM, Daniëls LA, Appelman Y, Maas AHEM, de Vries S, Jóźwiak K, Aleman BMP, van Leeuwen FE.

J Am Coll Cardiol. 2018 Dec 25;72(25):3374-3375. doi: 10.1016/j.jacc.2018.10.030. No abstract available.

PMID:
30573037
11.

High prevalence of advanced colorectal neoplasia and serrated polyposis syndrome in Hodgkin lymphoma survivors.

Rigter LS, Spaander MCW, Aleman BMP, Bisseling TM, Moons LM, Cats A, Lugtenburg PJ, Janus CPM, Petersen EJ, Roesink JM, van der Maazen RWM, Snaebjornsson P, Kuipers EJ, Bruno MJ, Dekker E, Meijer GA, de Boer JP, van Leeuwen FE, van Leerdam ME.

Cancer. 2019 Mar 15;125(6):990-999. doi: 10.1002/cncr.31903. Epub 2018 Dec 18.

12.

Gross tumour delineation on computed tomography and positron emission tomography-computed tomography in oesophageal cancer: A nationwide study.

Nowee ME, Voncken FEM, Kotte ANTJ, Goense L, van Rossum PSN, van Lier ALHMW, Heijmink SW, Aleman BMP, Nijkamp J, Meijer GJ, Lips IM; Dutch National Platform for Radiotherapy of Gastrointestinal Tumours (LPRGE) group.

Clin Transl Radiat Oncol. 2018 Oct 26;14:33-39. doi: 10.1016/j.ctro.2018.10.003. eCollection 2019 Jan.

13.

Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: a collaborative study by ILROG.

Brady JL, Binkley MS, Hajj C, Chelius M, Chau K, Balogh A, Levis M, Filippi AR, Jones M, Mac Manus M, Wirth A, Oguchi M, Vistisen AK, Andraos TY, Ng AK, Aleman BMP, Choi SH, Kirova Y, Hardy S, Reinartz G, Eich HT, Bratman SV, Constine LS, Suh CO, Dabaja B, El-Galaly TC, Hodgson DC, Ricardi U, Yahalom J, Hoppe RT, Mikhaeel NG.

Blood. 2019 Jan 17;133(3):237-245. doi: 10.1182/blood-2018-04-843540. Epub 2018 Nov 16. Erratum in: Blood. 2019 Jul 18;134(3):331.

PMID:
30446493
14.

Comparing causes of death of Hodgkin lymphoma and breast cancer patients between medical records and cause-of-death statistics.

de Vries S, Schaapveld M, Kardaun JW, de Bruin KH, Krol AD, Lugtenburg PJ, Jacobse JN, Aleman BM, van Leeuwen FE.

Clin Epidemiol. 2018 Oct 16;10:1523-1531. doi: 10.2147/CLEP.S161359. eCollection 2018.

15.

Radiation Dose-Response for Risk of Myocardial Infarction in Breast Cancer Survivors.

Jacobse JN, Duane FK, Boekel NB, Schaapveld M, Hauptmann M, Hooning MJ, Seynaeve CM, Baaijens MHA, Gietema JA, Darby SC, van Leeuwen FE, Aleman BMP, Taylor CW.

Int J Radiat Oncol Biol Phys. 2019 Mar 1;103(3):595-604. doi: 10.1016/j.ijrobp.2018.10.025. Epub 2018 Oct 29.

16.

Risk of diabetes after para-aortic radiation for testicular cancer.

Groot HJ, Gietema JA, Aleman BMP, Incrocci L, de Wit R, Witjes JA, Groenewegen G, de Brouwer P, Meijer OWM, Hulshof MCCM, van den Berg HA, Smilde TJ, Vanneste BGL, Aarts MJ, van den Bergh ACM, Kerst JM, van den Belt-Dusebout AW, Lubberts S, Jóźwiak K, Horenblas S, van Leeuwen FE, Schaapveld M.

Br J Cancer. 2018 Oct;119(7):901-907. doi: 10.1038/s41416-018-0248-x. Epub 2018 Oct 9.

PMID:
30297773
17.

Rationale and design of a cohort study on primary ovarian insufficiency in female survivors of Hodgkin's lymphoma: influence on long-term adverse effects (SOPHIA).

Krul IM, Opstal-van Winden AWJ, Zijlstra JM, Appelman Y, Schagen SB, Meijboom LJ, Serné E, Lambalk CB, Lips P, van Dulmen-den Broeder E, Hauptmann M, Daniëls LA, Aleman BMP, van Leeuwen FE.

BMJ Open. 2018 Sep 11;8(9):e018120. doi: 10.1136/bmjopen-2017-018120.

18.

Risk of benign meningioma after childhood cancer in the DCOG-LATER cohort: contributions of radiation dose, exposed cranial volume, and age.

Kok JL, Teepen JC, van Leeuwen FE, Tissing WJE, Neggers SJCMM, van der Pal HJ, Loonen JJ, Bresters D, Versluys B, van den Heuvel-Eibrink MM, van Dulmen-den Broeder E, van der Heiden-van der Loo M, Aleman BMP, Daniels LA, Haasbeek CJA, Hoeben B, Janssens GO, Maduro JH, Oldenburger F, van Rij C, Tersteeg RJHA, Hauptmann M; DCOG-LATER Study Group , Kremer LCM, Ronckers CM.

Neuro Oncol. 2019 Feb 19;21(3):392-403. doi: 10.1093/neuonc/noy124.

PMID:
30099534
19.

Cardiovascular disease incidence after internal mammary chain irradiation and anthracycline-based chemotherapy for breast cancer.

Boekel NB, Jacobse JN, Schaapveld M, Hooning MJ, Gietema JA, Duane FK, Taylor CW, Darby SC, Hauptmann M, Seynaeve CM, Baaijens MHA, Sonke GS, Rutgers EJT, Russell NS, Aleman BMP, van Leeuwen FE.

Br J Cancer. 2018 Aug;119(4):408-418. doi: 10.1038/s41416-018-0159-x. Epub 2018 Aug 1.

20.

Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Eichenauer DA, Aleman BMP, André M, Federico M, Hutchings M, Illidge T, Engert A, Ladetto M; ESMO Guidelines Committee.

Ann Oncol. 2018 Oct 1;29(Suppl 4):iv19-iv29. doi: 10.1093/annonc/mdy080. No abstract available.

PMID:
29796651
21.

DW-MRI and DCE-MRI are of complementary value in predicting pathologic response to neoadjuvant chemoradiotherapy for esophageal cancer.

Heethuis SE, Goense L, van Rossum PSN, Borggreve AS, Mook S, Voncken FEM, Bartels-Rutten A, Aleman BMP, van Hillegersberg R, Ruurda JP, Meijer GJ, Lagendijk JJW, van Lier ALHMW.

Acta Oncol. 2018 Sep;57(9):1201-1208. doi: 10.1080/0284186X.2018.1473637. Epub 2018 May 21.

PMID:
29781342
22.

Retrospective methods to estimate radiation dose at the site of breast cancer development after Hodgkin lymphoma radiotherapy.

Russell NS, Krul IM, van Eggermond AM, Aleman BMP, Cooke R, Kuiper S, Allen SD, Wallis MG, Llanas D, Diallo I, de Vathaire F, Smith SA, Hauptmann M, Broeks A, Swerdlow AJ, Van Leeuwen FE.

Clin Transl Radiat Oncol. 2017 Oct 24;7:20-27. doi: 10.1016/j.ctro.2017.09.004. eCollection 2017 Dec.

23.

Double somatic mutations in mismatch repair genes are frequent in colorectal cancer after Hodgkin's lymphoma treatment.

Rigter LS, Snaebjornsson P, Rosenberg EH, Atmodimedjo PN, Aleman BM, Ten Hoeve J, Geurts-Giele WR; PALGA group, van Ravesteyn TW, Hoeksel J, Meijer GA, Te Riele H, van Leeuwen FE, Dinjens WN, van Leerdam ME.

Gut. 2018 Mar;67(3):447-455. doi: 10.1136/gutjnl-2016-312608. Epub 2016 Nov 8.

PMID:
29439113
24.

High burden of subsequent malignant neoplasms and cardiovascular disease in long-term Hodgkin lymphoma survivors.

de Vries S, Schaapveld M, van Nimwegen FA, Jóźwiak K, Lugtenburg PJ, Daniëls LA, Roesink JM, van der Maazen RWM, Kok WEM, Aleman BMP, van Leeuwen FE.

Br J Cancer. 2018 Mar 20;118(6):887-895. doi: 10.1038/bjc.2017.476. Epub 2018 Jan 30.

25.

Comparison of 36 Gy, 20 Gy, or No Radiation Therapy After 6 Cycles of EBVP Chemotherapy and Complete Remission in Early-Stage Hodgkin Lymphoma Without Risk Factors: Results of the EORT-GELA H9-F Intergroup Randomized Trial.

Thomas J, Fermé C, Noordijk EM, Morschhauser F, Girinsky T, Gaillard I, Lugtenburg PJ, André M, Lybeert MLM, Stamatoullas A, Beijert M, Hélias P, Eghbali H, Gabarre J, van der Maazen RWM, Jaubert J, Bouabdallah K, Boulat O, Roesink JM, Christian B, Ong F, Bordessoule D, Tertian G, Gonzalez H, Vranovsky A, Quittet P, Tirelli U, de Jong D, Audouin J, Aleman BMP, Henry-Amar M.

Int J Radiat Oncol Biol Phys. 2018 Apr 1;100(5):1133-1145. doi: 10.1016/j.ijrobp.2017.10.015. Epub 2017 Oct 27.

PMID:
29229324
26.

Radiation-induced liver injury mimicking liver metastases on FDG-PET-CT after chemoradiotherapy for esophageal cancer : A retrospective study and literature review.

Voncken FEM, Aleman BMP, van Dieren JM, Grootscholten C, Lalezari F, van Sandick JW, Steinberg JD, Vegt E.

Strahlenther Onkol. 2018 Feb;194(2):156-163. doi: 10.1007/s00066-017-1217-7. Epub 2017 Oct 19.

PMID:
29051991
27.

Early-stage mantle cell lymphoma: a retrospective analysis from the International Lymphoma Radiation Oncology Group (ILROG).

Dabaja BS, Zelenetz AD, Ng AK, Tsang RW, Qi S, Allen PK, Hodgson D, Ricardi U, Hoppe RT, Advani R, Mauch PM, Constine LS, Specht L, Li Y, Terezakis SA, Wirth A, Reinartz G, Eich HT, Aleman BMP, Barr P, Yahalom J.

Ann Oncol. 2017 Sep 1;28(9):2185-2190. doi: 10.1093/annonc/mdx334.

PMID:
28911068
28.

Breast Cancer Risk After Radiation Therapy for Hodgkin Lymphoma: Influence of Gonadal Hormone Exposure.

Krul IM, Opstal-van Winden AWJ, Aleman BMP, Janus CPM, van Eggermond AM, De Bruin ML, Hauptmann M, Krol ADG, Schaapveld M, Broeks A, Kooijman KR, Fase S, Lybeert ML, Zijlstra JM, van der Maazen RWM, Kesminiene A, Diallo I, de Vathaire F, Russell NS, van Leeuwen FE.

Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):843-853. doi: 10.1016/j.ijrobp.2017.07.016. Epub 2017 Jul 18.

PMID:
28888722
29.

Advanced Age is Not a Contraindication for Treatment With Curative Intent in Esophageal Cancer.

Voncken FEM, van der Kaaij RT, Sikorska K, van Werkhoven E, van Dieren JM, Grootscholten C, Snaebjornsson P, van Sandick JW, Aleman BMP.

Am J Clin Oncol. 2018 Sep;41(9):919-926. doi: 10.1097/COC.0000000000000390.

PMID:
28763327
30.

Infradiaphragmatic irradiation and high procarbazine doses increase colorectal cancer risk in Hodgkin lymphoma survivors.

van Eggermond AM, Schaapveld M, Janus CP, de Boer JP, Krol AD, Zijlstra JM, van der Maazen RW, Kremer LC, van Leerdam ME, Louwman MW, Visser O, De Bruin ML, Aleman BM, van Leeuwen FE.

Br J Cancer. 2017 Jul 25;117(3):306-314. doi: 10.1038/bjc.2017.177. Epub 2017 Jun 20.

31.

Colorectal cancer surveillance in Hodgkin lymphoma survivors at increased risk of therapy-related colorectal cancer: study design.

Rigter LS, Spaander MC, Moons LM, Bisseling TM, Aleman BM, de Boer JP, Lugtenburg PJ, Janus CP, Petersen EJ, Roesink JM, Raemaekers JM, van der Maazen RW, Cats A, Bleiker EM, Snaebjornsson P, Carvalho B, Lansdorp-Vogelaar I, Jóźwiak K, Te Riele H, Meijer GA, van Leeuwen FE, van Leerdam ME.

BMC Cancer. 2017 Feb 7;17(1):112. doi: 10.1186/s12885-017-3089-8.

32.

Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines.

van Nimwegen FA, Ntentas G, Darby SC, Schaapveld M, Hauptmann M, Lugtenburg PJ, Janus CPM, Daniels L, van Leeuwen FE, Cutter DJ, Aleman BMP.

Blood. 2017 Apr 20;129(16):2257-2265. doi: 10.1182/blood-2016-09-740332. Epub 2017 Jan 31.

33.

Stomach Cancer Following Hodgkin Lymphoma, Testicular Cancer and Cervical Cancer: A Pooled Analysis of Three International Studies with a Focus on Radiation Effects.

Gilbert ES, Curtis RE, Hauptmann M, Kleinerman RA, Lynch CF, Stovall M, Smith SA, Weathers R, Andersson M, Dores GM, Fraumeni JF Jr, Fossa SD, Hall P, Hodgson DC, Holowaty EJ, Joensuu H, Johannesen TB, Langmark F, Kaijser M, Pukkala E, Rajaraman P, Storm HH, Vaalavirta L, van den Belt-Dusebout AW, Aleman BM, Travis LB, Morton LM, van Leeuwen FE.

Radiat Res. 2017 Feb;187(2):186-195. doi: 10.1667/RR14453.1. Epub 2017 Jan 24.

34.

Increased pancreatic cancer risk following radiotherapy for testicular cancer.

Hauptmann M, Børge Johannesen T, Gilbert ES, Stovall M, van Leeuwen FE, Rajaraman P, Smith SA, Weathers RE, Aleman BM, Andersson M, Curtis RE, Dores GM, Fraumeni JF Jr, Hall P, Holowaty EJ, Joensuu H, Kaijser M, Kleinerman RA, Langmark F, Lynch CF, Pukkala E, Storm HH, Vaalavirta L, van den Belt-Dusebout AW, Morton LM, Fossa SD, Travis LB.

Br J Cancer. 2016 Sep 27;115(7):901-8. doi: 10.1038/bjc.2016.272. Epub 2016 Sep 6.

35.

Reply to D. Vordermark and T. Pelz and R. Mazzola et al.

van Nimwegen FA, Cutter DJ, Schaapveld M, Darby SC, Aleman BM, van Leeuwen FE.

J Clin Oncol. 2016 Aug 20;34(24):2941-2. doi: 10.1200/JCO.2016.67.4358. Epub 2016 May 2. No abstract available.

PMID:
27138579
36.

Cardiovascular Disease Risk in a Large, Population-Based Cohort of Breast Cancer Survivors.

Boekel NB, Schaapveld M, Gietema JA, Russell NS, Poortmans P, Theuws JC, Schinagl DA, Rietveld DH, Versteegh MI, Visser O, Rutgers EJ, Aleman BM, van Leeuwen FE.

Int J Radiat Oncol Biol Phys. 2016 Apr 1;94(5):1061-72. doi: 10.1016/j.ijrobp.2015.11.040. Epub 2015 Dec 14.

PMID:
27026313
37.

Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma.

Schaapveld M, Aleman BM, van Eggermond AM, Janus CP, Krol AD, van der Maazen RW, Roesink J, Raemaekers JM, de Boer JP, Zijlstra JM, van Imhoff GW, Petersen EJ, Poortmans PM, Beijert M, Lybeert ML, Mulder I, Visser O, Louwman MW, Krul IM, Lugtenburg PJ, van Leeuwen FE.

N Engl J Med. 2015 Dec 24;373(26):2499-511. doi: 10.1056/NEJMoa1505949.

38.

Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trials.

Maraldo MV, Giusti F, Vogelius IR, Lundemann M, van der Kaaij MA, Ramadan S, Meulemans B, Henry-Amar M, Aleman BM, Raemaekers J, Meijnders P, Moser EC, Kluin-Nelemans HC, Feugier P, Casasnovas O, Fortpied C, Specht L; European Organisation for Research and Treatment of Cancer (EORTC) Lymphoma Group.

Lancet Haematol. 2015 Nov;2(11):e492-502. doi: 10.1016/S2352-3026(15)00153-2. Epub 2015 Oct 22.

PMID:
26686259
39.

[The BETER survivorship care initiative for Hodgkin lymphoma; tailored survivorship care for late effects of treatment].

Dekker N, van 't Veer MB, Aleman BM, van Leeuwen FE, Raemaekers JM.

Ned Tijdschr Geneeskd. 2015;159:A9269. Dutch.

PMID:
26577382
40.

Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma.

van Nimwegen FA, Schaapveld M, Cutter DJ, Janus CP, Krol AD, Hauptmann M, Kooijman K, Roesink J, van der Maazen R, Darby SC, Aleman BM, van Leeuwen FE.

J Clin Oncol. 2016 Jan 20;34(3):235-43. doi: 10.1200/JCO.2015.63.4444. Epub 2015 Nov 16.

PMID:
26573075
41.

Cardiovascular disease after cancer therapy.

Aleman BM, Moser EC, Nuver J, Suter TM, Maraldo MV, Specht L, Vrieling C, Darby SC.

EJC Suppl. 2014 Jun;12(1):18-28. doi: 10.1016/j.ejcsup.2014.03.002. Epub 2014 May 29.

42.

Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk.

van Nimwegen FA, Schaapveld M, Janus CP, Krol AD, Petersen EJ, Raemaekers JM, Kok WE, Aleman BM, van Leeuwen FE.

JAMA Intern Med. 2015 Jun;175(6):1007-17. doi: 10.1001/jamainternmed.2015.1180.

PMID:
25915855
43.

Simple method to estimate mean heart dose from Hodgkin lymphoma radiation therapy according to simulation X-rays.

van Nimwegen FA, Cutter DJ, Schaapveld M, Rutten A, Kooijman K, Krol AD, Janus CP, Darby SC, van Leeuwen FE, Aleman BM.

Int J Radiat Oncol Biol Phys. 2015 May 1;92(1):153-60. doi: 10.1016/j.ijrobp.2015.02.019.

PMID:
25863762
44.

[Hypofractionated adjuvant radiotherapy for breast cancer: no signs of increased risk of cardiotoxicity].

Aleman BM, van Leeuwen FE.

Ned Tijdschr Geneeskd. 2015;159:A8856. Dutch.

PMID:
25827153
45.

Risk of valvular heart disease after treatment for Hodgkin lymphoma.

Cutter DJ, Schaapveld M, Darby SC, Hauptmann M, van Nimwegen FA, Krol AD, Janus CP, van Leeuwen FE, Aleman BM.

J Natl Cancer Inst. 2015 Feb 23;107(4). pii: djv008. doi: 10.1093/jnci/djv008. Print 2015 Apr.

46.

Increased stomach cancer risk following radiotherapy for testicular cancer.

Hauptmann M, Fossa SD, Stovall M, van Leeuwen FE, Johannesen TB, Rajaraman P, Gilbert ES, Smith SA, Weathers RE, Aleman BM, Andersson M, Curtis RE, Dores GM, Fraumeni JF, Hall P, Holowaty EJ, Joensuu H, Kaijser M, Kleinerman RA, Langmark F, Lynch CF, Pukkala E, Storm HH, Vaalavirta L, van den Belt-Dusebout AW, Travis LB, Morton LM.

Br J Cancer. 2015 Jan 6;112(1):44-51. doi: 10.1038/bjc.2014.552. Epub 2014 Nov 4.

47.

Risk of esophageal cancer following radiotherapy for Hodgkin lymphoma.

Morton LM, Gilbert ES, Stovall M, van Leeuwen FE, Dores GM, Lynch CF, Hall P, Smith SA, Weathers RE, Storm HH, Hodgson DC, Kleinerman RA, Joensuu H, Johannesen TB, Andersson M, Holowaty EJ, Kaijser M, Pukkala E, Vaalavirta L, Fossa SD, Langmark F, Travis LB, Lamart S, Simon SL, Fraumeni JF Jr, Aleman BM, Curtis RE.

Haematologica. 2014 Oct;99(10):e193-6. doi: 10.3324/haematol.2014.108258. No abstract available.

48.

Pancreatic cancer risk after treatment of Hodgkin lymphoma.

Dores GM, Curtis RE, van Leeuwen FE, Stovall M, Hall P, Lynch CF, Smith SA, Weathers RE, Storm HH, Hodgson DC, Kleinerman RA, Joensuu H, Johannesen TB, Andersson M, Holowaty EJ, Kaijser M, Pukkala E, Vaalavirta L, Fossa SD, Langmark F, Travis LB, Fraumeni JF Jr, Aleman BM, Morton LM, Gilbert ES.

Ann Oncol. 2014 Oct;25(10):2073-9. doi: 10.1093/annonc/mdu287. Epub 2014 Jul 25.

49.

Risk of diabetes mellitus in long-term survivors of Hodgkin lymphoma.

van Nimwegen FA, Schaapveld M, Janus CP, Krol AD, Raemaekers JM, Kremer LC, Stovall M, Aleman BM, van Leeuwen FE.

J Clin Oncol. 2014 Oct 10;32(29):3257-63. doi: 10.1200/JCO.2013.54.4379. Epub 2014 Aug 25.

PMID:
25154821
50.

Detecting interval metastases and response assessment using 18F-FDG PET/CT after neoadjuvant chemoradiotherapy for esophageal cancer.

Stiekema J, Vermeulen D, Vegt E, Voncken FE, Aleman BM, Sanders J, Boot H, van Sandick JW.

Clin Nucl Med. 2014 Oct;39(10):862-7. doi: 10.1097/RLU.0000000000000517.

PMID:
25140549

Supplemental Content

Loading ...
Support Center